Positive Phase II for Polaris lead product in mesothelioma
This article was originally published in Scrip
Executive Summary
Privately held biopharmaceutical firm Polaris Group has reported positive Phase II results for its lead product, anticancer ADI-PEG 20, in malignant pleural mesothelioma (MPM), what looks to be its second indication.